Biessen, D. van der

patient panobinostat study f 60008 level phase cancer ketoconazole grade triptolide sample inhibitor pharmacokinetic treatment 18 mg /m day 1 cyp 3a inhibitor dose level toxicity extension phase apoptosi plasma blood increase concentration core phase analysis table cycle caspase -3 activity range activation parameter nf-jb effect number activity period event therapy cyp 3a hypophosphatemia administration cyp 3a inhibitors fi rst cycle extension phosphate tumor study drug pharmacokinetic parameters subset pathway dose levels interaction cancer 4 5 fi rst dose phase i study 12 mg /m trial caspase histone fl ow cytometry class infusion result lymphoma lymphocytes ratio lymphocyte subsets monocyte plasma concentrations days 1 journal safety deacetylase pharmacol enzyme death drug –drug interactions response